Chengdu Kanghong Pharmaceutical Group (002773.SZ) has obtained the registration certificate for Brivaracetam tablets.

Chengdu Kanghong Pharmaceutical Group (002773.SZ) announced that the company has recently received the "Drug Registration Certificate" for Brexpiprazole Tablets issued by the National Medical Products Administration (Certificate No: 2025S03922, 2025S03923), and it has been approved for registration. The mechanism of action of Brexpiprazole for the treatment of schizophrenia is not yet clear, but it may involve partial agonist activity at 5-HT1A and dopamine D2 receptors, as well as antagonist activity at 5-HT2A receptors.